Skip to main content
Clinical Trials/NCT02642731
NCT02642731
Completed
Not Applicable

Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty- a Pilot Study

Kuopio University Hospital1 site in 1 country30 target enrollmentSeptember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arthroplasty, Replacement, Knee
Sponsor
Kuopio University Hospital
Enrollment
30
Locations
1
Primary Endpoint
Renal function
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Sensitive renal markers have been studied abundantly in connection with open heart, liver and transplantation surgery; however in major orthopaedic surgery their use is anecdotal. The aim of the present study is to evaluate use of sensitive renal markers, NGAL (Neutrophil gelatinase associated lipocalin ), KIM-1 (Kidney injury molecule- 1), LFABP (liver-type fatty acid-binding protein), and IL-18 (interleukin -18), in patients coming for elective TKA (total knee arthroplasty) as a pilot study before large study concerning acute kidney injury in orthopaedic surgery.

Detailed Description

Acute renal deterioration is a serious adverse event in elective surgery. Serum creatinine based diagnostics of acute kidney injury may delay diagnosis and produce false negative results since serum creatinine is affected by diet, muscle mass, used hydration therapy. In recent times new markers have been developed and tested in order to find sensitive, fast and reliable marker of renal deterioration.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
December 2015
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kuopio University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Merja Kokki

MD, PhD

Kuopio University Hospital

Eligibility Criteria

Inclusion Criteria

  • informed consent
  • allergy to NSAIDs

Exclusion Criteria

  • no informed consent

Outcomes

Primary Outcomes

Renal function

Time Frame: time zero hours to 48 hours

S-creatinine, Cystatin C, estimated GFR

Secondary Outcomes

  • Concentraton of sensitive renal markers(time zero hours to 24 hours)

Study Sites (1)

Loading locations...

Similar Trials